NCT03012620View on ClinicalTrials.gov

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

PHASE2CompletedINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

December 26, 2022

Study Completion Date

December 14, 2023

Conditions
SarcomaOvarian NeoplasmCentral Nervous System NeoplasmThyroid NeoplasmCarcinoma, NeuroendocrineNeoplasms, Germ Cell and EmbryonalNK/T-cell Lymphoma
Interventions
DRUG

Pembrolizumab

Treatment

Trial Locations (1)

Unknown

Gustave Roussy Cancer Campus, Villejuif

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

Ligue contre le cancer, France

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

UNICANCER

OTHER

NCT03012620 - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | Biotech Hunter | Biotech Hunter